NCT00369187已完成4 期
Study of a Large Protein Molecule Administered With Escalating Doses of Recombinant Human Hyaluronidase
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 15
- 主要终点
- AUC
研究概览
简要总结
This Phase IV, dose escalation, within-patient controlled study of pharmacokinetics (PK), safety and tolerability compares a single dose administration of a large protein molecule without recombinant human hyaluronidase (rHuPH20) to a single dose administration of the large molecule with escalating doses of rHuPH20. The study hypothesizes that an optimal dose of rHuPH20 will increase the bioavailability of large molecule drug administration.
详细描述
Sequential enrollment into four rHuPH20 dose cohorts.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males or females at least 18 years of age with RA treated with MTX who have been treated with:
- •co-injected large molecule protein for at least two cycles, and
- •have had stable disease with no symptom flares in the previous 30 days.
- •AST (SGOT) and ALT (SGPT) within normal range within 7 days prior to entry in the study.
- •Adequate venous access in at least one extremity.
- •A negative pregnancy test (if female of child-bearing potential) within 7 days prior to entry in the study.
- •Decision-making capacity.
- •Signed, written IRB-approved informed consent.
排除标准
- •Unacceptable toxicity to the large molecule protein, or contraindication to or other reason to not continue the large molecule protein per the package insert (e.g., active or latent tuberculosis, chronic or localized infections, or concurrent treatment with anakinra).
- •History of active tuberculosis, or known positive tuberculin skin test unless the patient has successfully completed a nine-month course of isoniazid therapy.
- •Concurrent use of any disease-modifying anti-rheumatic drug except the large molecule protein and MTX.
- •Any anticipation that the dose of the large molecule protein or MTX would be changed within 4 weeks following entry in the study.
- •Known allergy to hyaluronidase or any hyaluronidase product.
- •Known allergy to bee or vespid venom.
- •Contraindication to IV heparin lock or known hypersensitivity to heparin.
- •Edema, infection, or any other lower extremity or pelvic disorder that might affect subcutaneous absorption from the thigh.
- •Presence of any other medical condition that would present an unacceptable safety risk to the patient.
- •Participation in a study of any investigational drug or device within 30 days of enrollment in this study.
结局指标
主要结局
AUC
次要结局
- Tmax, Cmax, half-lives, injection site reactions, safety and tolerability, NAbs
研究者
相似试验
终止
1 期
A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia (AML)NCT03125876Sunshine Lake Pharma Co., Ltd.12
进行中（未招募）
1 期
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Lymphoma, B-CellSmall Lymphocytic LymphomaWaldenstrom MacroglobulinemiaDiffuse Large B Cell LymphomaRichter's TransformationMarginal Zone LymphomaChronic Lymphocytic LeukemiaFollicular LymphomaMantle Cell LymphomaNCT03162536ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)190
终止
2 期
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart FailureAcute Heart FailureNCT02151383Novartis Pharmaceuticals12
已完成
1 期
HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast CancerAdvanced Breast CancerNCT00719875Yale University24
终止
1 期
A Study of PF-07260437 in Advanced or Metastatic Solid TumorsOvarian NeoplasmsEndometrial NeoplasmsBreast NeoplasmsNCT05067972Pfizer30